Ceryvyn Therapeutics Ltd
OPT
Kedudukan dalam Saham
#31800
Opthea Limited is an Australian clinical-stage biopharmaceutical company... Opthea Limited is an Australian clinical-stage biopharmaceutical company focused on developing and commercializing therapies primarily for eye diseases. The foundation of its development efforts lies in its intellectual property portfolio, which targets Vascular Endothelial Growth Factors (VEGF-C, VEGF-D, and VEGF Receptor-3). This technology is designed to address conditions linked to the growth of blood and lymphatic vessels, as well as vascular leakage. The company's leading asset, OPT 302, is a soluble form of VEGFR3 currently undergoing clinical trials. This novel therapy aims to treat wet neovascular age-related macular degeneration (wet AMD) and diabetic macular edema (DME). OPT 302 is distinguished as a first-in-class VEGF-C/D inhibitor, intended to be used in conjunction with VEGF-A inhibitors for the treatment of wet AMD and various other retinal diseases. Originally incorporated in 1984 as Circadian Technologies Limited, the company rebranded to Opthea Limited in December 2015 and is headquartered in South Yarra, Australia.
Harga Saham
$0.00846342
Disegerakkan terakhir: 2026-07-27
Modal Pasaran
$11.27M
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
-99.75%
Negara
AU
Perdagangan Ceryvyn Therapeutics Ltd (OPT)
Kategori
Healthcare
Sejarah harga saham bagi Ceryvyn Therapeutics Ltd (OPT)
Harga penutupan tertinggi: $3.41 pada 2025-04-01
Harga penutupan terendah: $13.17 pada 2020-10-01
Harga penutupan terendah: $13.17 pada 2020-10-01
Sejarah harga saham Ceryvyn Therapeutics Ltd dari 2020 hingga 2026
Prestasi harga saham tahunan
| Tahun | Prestasi |
|---|---|
| 2025 | -4.06% |
| 2024 | 37.44% |
| 2023 | -49.05% |
| 2022 | -27.97% |
| 2021 | -41.46% |
| 2020 | 0.00% |
Harga saham bagi syarikat atau pesaing serupa
| Syarikat | Harga saham | Perubahan 1thn% | Negara |
|---|---|---|---|
| $516.85 | 21.25% |
US
|
|
| $247.28 | 799.51% |
US
|
|
| $138.33 | -3.31% |
AU
|
|
| $882.70 | 5.74% |
NL
|
|
| $753.36 | 7.47% |
CH
|
